Drug resistance and combating drug resistance in cancer

Abstract

Cancer is the second leading cause of death in the US. Current major treatments for cancer management include surgery, cytotoxic chemotherapy, targeted therapy, radiation therapy, endocrine therapy and immunotherapy. Despite the endeavors and achievements made in treating cancers during the past decades, resistance to classical chemotherapeutic agents and/or novel targeted drugs continues to be a major problem in cancer therapies. Drug resistance, either existing before treatment (intrinsic) or generated after therapy (acquired), is responsible for most relapses of cancer, one of the major causes of death of the disease. Heterogeneity among patients and tumors, and the versatility of cancer to circumvent therapies make drug resistance more challenging to deal with. Better understanding the mechanisms of drug resistance is required to provide guidance to future cancer treatment and achieve better outcomes. In this review, intrinsic and acquired resistance will be discussed. In addition, new discoveries in mechanisms of drug resistance will be reviewed. Particularly, we will highlight roles of ATP in drug resistance by discussing recent findings of exceptionally high levels of intratumoral extracellular ATP as well as intracellular ATP internalized from extracellular environment. The complexity of drug resistance development suggests that combinational and personalized therapies, which should take ATP into consideration, might provide better strategies and improved efficacy for fighting drug resistance in cancer.

Keywords

Cancer stem cells / epithelial mesenchymal transition / ATP binding cassette transporters / extracellular ATP / macropinocytosis / epigenetics / microRNA

References

[1] National Center for Health StatisticsHealth, United States, 2015: with special feature on racial and ethnic health disparities.2016;Hyattsville, MD

[2] American Cancer Society2017;AtlantaAmerican Cancer Society

[3] Housman G,Heerboth S,Longacre M.Drug resistance in cancer: an overview..Cancers (Basel)2014;6:1769-92 PMCID:PMC4190567

[4] Rueff J.Cancer drug resistance: a brief overview from a genetic viewpoint..Methods Mol Biol2016;1395:1-18

[5] Holohan C,Longley DB.Cancer drug resistance: an evolving paradigm..Nat Rev Cancer2013;13:714-26

[6] Borst P.Cancer drug pan-resistance: pumps, cancer stem cells, quiescence, epithelial to mesenchymal transition, blocked cell death pathways, persisters or what?.Open Biol2012;2:120066 PMCID:PMC3376736

[7] Alfarouk KO,Taylor S,Muddathir AK.Resistance to cancer chemotherapy: failure in drug response from ADME to P-gp..Cancer Cell Int2015;15:71 PMCID:PMC4502609

[8] Urruticoechea A,Balart J,Viñals F.Recent advances in cancer therapy: an overview..Curr Pharm Des2010;16:3-10

[9] Baskar R,Yeo R.Cancer and radiation therapy: current advances and future directions..Int J Med Sci2012;9:193-9 PMCID:PMC3298009

[10] Damin DC.Evolving treatment strategies for colorectal cancer: a critical review of current therapeutic options..World J Gastroenterol2014;20:877 PMCID:PMC3921541

[11] Lumachi F,Basso SMM,Brunello A.Endocrine therapy of breast cancer..Curr Med Chem2011;18:513-22

[12] Khalil DN,Brentjens RJ.The future of cancer treatment: immunomodulation, CARs and combination immunotherapy..Nat Rev Clin Oncol2016;13:273-90 PMCID:PMC5551685

[13] Uramoto H.Recurrence after surgery in patients with NSCLC..Transl lung cancer Res2014;3:242-9 PMCID:PMC4367696

[14] Castells M,Delord JP.Implication of tumor microenvironment in chemoresistance: tumor-associated stromal cells protect tumor cells from cell death..Int J Mol Sci2012;13:9545-71 PMCID:PMC3431813

[15] O’Connor D,Caswell M,Cummins M.Early UK experience in the use of clofarabine in the treatment of relapsed and refractory paediatric acute lymphoblastic leukaemia..Br J Haematol2011;154:482-5

[16] Lippert T,Volm M.Intrinsic and acquired drug resistance in malignant tumors..Arzneimittelforschung2008;58:261-4

[17] Kelderman S,Haanen JB.Acquired and intrinsic resistance in cancer immunotherapy..Mol Oncol2014;8:1132-9 PMCID:PMC5528612

[18] Huang D,Huang H,Han Y.Cisplatin resistance in gastric cancer cells is associated with HER2 upregulation-induced epithelial-mesenchymal transition..Sci Rep2016;6:20502 PMCID:PMC4742832

[19] Kurrey NK,Joglekar AV,Chaskar PD.Snail and Slug mediate radioresistance and chemoresistance by antagonizing p53-mediated apoptosis and acquiring a stem-like phenotype in ovarian cancer cells..Stem Cells2009;27:2059-68

[20] Witta SE,Hirsch FR,Hedman K.Restoring E-cadherin expression increases sensitivity to epidermal growth factor receptor inhibitors in lung cancer cell lines..Cancer Res2006;66:944-50

[21] Sayan AE,Pal R,Ruddick A.SIP1 protein protects cells from DNA damage-induced apoptosis and has independent prognostic value in bladder cancer..Proc Natl Acad Sci U S A2009;106:14884-9 PMCID:PMC2736415

[22] Burrell RA,Bartek J.The causes and consequences of genetic heterogeneity in cancer evolution..Nature2013;501:338-45

[23] Kreso A.Evolution of the cancer stem cell model..Cell Stem Cell2014;14:275-91

[24] Turner NC.Genetic heterogeneity and cancer drug resistance..Lancet Oncol2012;13:e178-85

[25] Moulder S.Intrinsic resistance to chemotherapy in breast cancer..Women’s Heal2010;6:821-30

[26] Greaves M.Clonal evolution in cancer..Nature2012;481:306-13 PMCID:PMC3367003

[27] Kuczynski EA,Grothey A.Drug rechallenge and treatment beyond progression--implications for drug resistance..Nat Rev Clin Oncol2013;10:571-87 PMCID:PMC4540602

[28] Frank NY,Frank MH,Grindley J.The therapeutic promise of the cancer stem cell concept..J Clin Invest2010;120:41-50 PMCID:PMC2798700

[29] Viale A,Orleth A,Giuliani V.Cell-cycle restriction limits DNA damage and maintains self-renewal of leukaemia stem cells..Nature2009;457:51-6

[30] Eramo A,Zeuner A,Lotti F.Chemotherapy resistance of glioblastoma stem cells..Cell Death Differ2006;13:1238-41

[31] Hermann PC,Herrler T,Ellwart JW.Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer..Cell Stem Cell2007;1:313-23

[32] Gillet JP,Varma S,Bunkholt Elstrand M.Multidrug resistance-linked gene signature predicts overall survival of patients with primary ovarian serous carcinoma..Clin Cancer Res2012;18:3197-206 PMCID:PMC3376649

[33] Traverso N,Nitti M,Furfaro AL.Role of glutathione in cancer progression and chemoresistance..Oxid Med Cell Longev2013;2013:972913 PMCID:PMC3673338

[34] Ding L,Larson DE,Koboldt DC.Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing..Nature2012;481:506-10 PMCID:PMC3267864

[35] Quintás-Cardama A,Cortes JE.Mechanisms of primary and secondary resistance to imatinib in chronic myeloid leukemia..Cancer Control2009;16:122-31

[36] Jabbour EJ,Kantarjian HM.Resistance to tyrosine kinase inhibition therapy for chronic myelogenous leukemia: a clinical perspective and emerging treatment options..Clin Lymphoma Myeloma Leuk2013;13:515-29 PMCID:PMC4160831

[37] Kimura S,Kojima K.BCR-ABL point mutations and TKI treatment in CML patients..J Hematol Transfus2014;2:

[38] Challagundla KB,Neviani P,Murtadha M.Exosome-mediated transfer of microRNAs within the tumor microenvironment and neuroblastoma resistance to chemotherapy..J Natl Cancer Inst2015;107:djv135 PMCID:PMC4651042

[39] Vadlapatla R,Pal D.Mechanisms of drug resistance in cancer chemotherapy: coordinated role and regulation of efflux transporters and metabolizing enzymes..Curr Pharm Des2013;19:7126-40

[40] Wu Q,Nie Y,Fan D.Multi-drug resistance in cancer chemotherapeutics: Mechanisms and lab approaches..Cancer Lett2014;347:159-66

[41] Vasiliou V,Nebert DW.Human ATP-binding cassette (ABC) transporter family..Hum Genomics2009;3:281-90 PMCID:PMC2752038

[42] Wilkens S.Structure and mechanism of ABC transporters..F1000Prime Rep2015;7:14 PMCID:PMC4338842

[43] Sauna ZE,Ambudkar SV.Genomics and the mechanism of P-glycoprotein (ABCB1)..J Bioenerg Biomembr2007;39:481-7

[44] Lagas JS,Wagenaar E,van Tellingen O.P-glycoprotein (P-gp/Abcb1), Abcc2, and Abcc3 determine the pharmacokinetics of etoposide..Clin Cancer Res2010;16:130-40

[45] Lal S,Sandanaraj E,Ang PC.Influence of ABCB1 and ABCG2 polymorphisms on doxorubicin disposition in Asian breast cancer patients..Cancer Sci2008;99:816-23

[46] Vaidyanathan A,Gannon AL,Scott AL.ABCB1 (MDR1) induction defines a common resistance mechanism in paclitaxel- and olaparib-resistant ovarian cancer cells..Br J Cancer2016;115:431-41 PMCID:PMC4985349

[47] Satake K,Mitani Y,da Silva Bolzani V.Human ABCB1 confers cells resistance to cytotoxic guanidine alkaloids from Pterogyne nitens..Biomed Mater Eng2015;25:249-56

[48] Sharom FJ.ABC multidrug transporters: structure, function and role in chemoresistance..Pharmacogenomics2008;9:105-27

[49] Fojo AT,Slamon DJ,Gottesman MM.Expression of a multidrug-resistance gene in human tumors and tissues..Proc Natl Acad Sci U S A1987;84:265-9 PMCID:PMC304184

[50] Shaffer BC,Patel C,Bates SE.Drug resistance: still a daunting challenge to the successful treatment of AML..Drug Resist Updat2012;15:62-9 PMCID:PMC3348380

[51] Baudis M,Tung YH.ABCB1 over-expression and drug-efflux in acute lymphoblastic leukemia cell lines with t(17;19) and E2A-HLF expression..Pediatr Blood Cancer2006;47:757-64

[52] Peng XX,Wu HC.Overexpression of P-glycoprotein induces acquired resistance to imatinib in chronic myelogenous leukemia cells..Chin J Cancer2012;31:110-8 PMCID:PMC3777469

[53] Yin J.Multidrug resistance-associated protein 1 (MRP1/ABCC1) polymorphism: from discovery to clinical application..Zhong Nan Da Xue Xue Bao Yi Xue Ban2011;36:927-38 PMCID:PMC4297474

[54] Müller M,Zaman GJ,Scheper RJ.Overexpression of the gene encoding the multidrug resistance-associated protein results in increased ATP-dependent glutathione S-conjugate transport..Proc Natl Acad Sci U S A1994;91:13033-7 PMCID:PMC45575

[55] Cole SPC.Transport of glutathione and glutathione conjugates by MRP1..Trends Pharmacol Sci2006;27:438-46

[56] Cole SP.Multidrug resistance protein 1 (MRP1, ABCC1), a “multitasking” ATP-binding cassette (ABC) transporter..J Biol Chem2014;289:30880-8 PMCID:PMC4223294

[57] Munoz M,Haber M.Role of the MRP1/ABCC1 multidrug transporter protein in cancer..IUBMB Life2007;59:752-7

[58] Cho S,He X,Bhat U.Notch1 regulates the expression of the multidrug resistance gene ABCC1/MRP1 in cultured cancer cells..Proc Natl Acad Sci U S A2011;108:20778-83 PMCID:PMC3251103

[59] Stacy AE,Richardson DR.Molecular pharmacology of ABCG2 and Its role in chemoresistance..Mol Pharmacol2013;84:655-69

[60] Mao Q.Role of the breast cancer resistance protein (BCRP/ABCG2) in drug transport--an update..AAPS J2015;17:65-82 PMCID:PMC4287283

[61] Horsey AJ,Sarwat S.The multidrug transporter ABCG2: still more questions than answers Multidrug transporters in biology..Biochem Soc Trans2016;44:824-30 PMCID:PMC4900755

[62] Pan ST,He ZX,Zhou SF.Molecular mechanisms for tumour resistance to chemotherapy..Clin Exp Pharmacol Physiol2016;43:723-37

[63] Folmer Y,Blum HE.Reversal of drug resistance of hepatocellular carcinoma cells by adenoviral delivery of anti-ABCC2 antisense constructs..Cancer Gene Ther2007;14:875-84

[64] Balaji SA,Chamallamudi MR,Rangarajan A.Role of the drug transporter ABCC3 in breast cancer chemoresistance..PLoS One2016;11:e0155013 PMCID:PMC4865144

[65] Zhao Y,Yan A,Meng Q.ABCC3 as a marker for multidrug resistance in non-small cell lung cancer..Sci Rep2013;3:3120 PMCID:PMC3814586

[66] Wang Y,Zhou C.Erlotinib in the treatment of advanced non-small cell lung cancer: an update for clinicians..Ther Adv Med Oncol2012;4:19-29 PMCID:PMC3244201

[67] Gridelli C,Di Maio M,Cappuzzo F.Gefitinib as first-line treatment for patients with advanced non-small-cell lung cancer with activating epidermal growth factor receptor mutation: review of the evidence..Lung Cancer2011;71:249-57

[68] Tang J,Gadgeel SM,Ahmad A.Erlotinib resistance in lung cancer: current progress and future perspectives..Front Pharmacol2013;4:15 PMCID:PMC3570789

[69] Bell DW,Okimoto RA,Sordella R.Inherited susceptibility to lung cancer may be associated with the T790M drug resistance mutation in EGFR..Nat Genet2005;37:1315-6

[70] Ma C,Song Y.T790M and acquired resistance of EGFR TKI: a literature review of clinical reports..J Thorac Dis2011;3:10-8 PMCID:PMC3256494

[71] Chan BA.Targeted therapy for non-small cell lung cancer: current standards and the promise of the future..Transl lung cancer Res2015;4:36-54 PMCID:PMC4367711

[72] Liao BC,Yang JC.Second and third-generation epidermal growth factor receptor tyrosine kinase inhibitors in advanced nonsmall cell lung cancer..Curr Opin Oncol2015;27:94-101

[73] Wang S,Liu D.Third-generation inhibitors targeting EGFR T790M mutation in advanced non-small cell lung cancer..J Hematol Oncol2016;9:34 PMCID:PMC4830020

[74] Wang S,Liu C,Liu D.EGFR C797S mutation mediates resistance to third-generation inhibitors in T790M-positive non-small cell lung cancer..J Hematol Oncol2016;9:59 PMCID:PMC4957905

[75] Jia Y,Park E,Manuia M.Overcoming EGFR(T790M) and EGFR(C797S) resistance with mutant-selective allosteric inhibitors..Nature2016;534:129-32 PMCID:PMC4929832

[76] Wang S,Liu D.EAI045: the fourth-generation EGFR inhibitor overcoming T790M and C797S resistance..Cancer Lett2017;385:51-4

[77] MacGregor Schafer J,Bentrem DJ,Jordan VC.Allosteric silencing of activating function 1 in the 4-hydroxytamoxifen estrogen receptor complex is induced by substituting glycine for aspartate at amino acid 351..Cancer Res2000;60:5097-105

[78] Likhite VS,Kim K,Katzenellenbogen JA.Kinase-specific phosphorylation of the estrogen receptor changes receptor interactions with ligand, deoxyribonucleic acid, and coregulators associated with alterations in estrogen and tamoxifen activity..Mol Endocrinol2006;20:3120-32

[79] Avvaru SP,Aminbhavi TM,Dash A.Aromatase inhibitors evolution as potential class of drugs in the treatment of postmenopausal breast cancer women..Mini Rev Med Chem2018;18:609-21

[80] Helleday T,Lundin C,Sharma RA.DNA repair pathways as targets for cancer therapy..Nat Rev Cancer2008;8:193-204

[81] de Angelis PM,Kravik KL,Tunheim SH.Molecular characterizations of derivatives of HCT116 colorectal cancer cells that are resistant to the chemotherapeutic agent 5-fluorouracil..Int J Oncol2004;24:1279-88

[82] De Angelis PM,Kravik KL.Cellular response to 5-fluorouracil (5-FU) in 5-FU-resistant colon cancer cell lines during treatment and recovery..Mol Cancer2006;5:20 PMCID:PMC1524802

[83] Campisi J.Aging, cellular senescence, and cancer..Annu Rev Physiol2013;75:685-705 PMCID:PMC4166529

[84] Gordon RR.Cellular senescence and cancer chemotherapy resistance..Drug Resist Updat2012;15:123-31 PMCID:PMC3348393

[85] Schmitt CA,Yang M,Baranov E.A senescence program controlled by p53 and p16INK4a contributes to the outcome of cancer therapy..Cell2002;109:335-46

[86] Demaria M,Chang J,Liu S.Cellular senescence promotes adverse effects of chemotherapy and cancer relapse..Cancer Discov2017;7:165-76 PMCID:PMC5296251

[87] Roberson RS,Vallieres E,Wu DY.Escape from therapy-induced accelerated cellular senescence in p53-null lung cancer cells and in human lung cancers..Cancer Res2005;65:2795-803

[88] Sabisz M.Cancer stem cells and escape from drug-induced premature senescence in human lung tumor cells: implications for drug resistance and in vitro drug screening models..Cell Cycle Georget Tex2009;8:3208-17

[89] Milanovic M,Belenki D,Zhao Z.Senescence-associated reprogramming promotes cancer stemness..Nature2018;553:96-100

[90] Lantermann AB,Sharma SV.The role of epigenetics in drug resistance in cancer..Epigenetic Diagnosis Ther2016;1:106-19

[91] Easwaran H,Baylin SB.Cancer epigenetics: tumor heterogeneity, plasticity of stem-like states, and drug resistance..Mol Cell2014;54:716-27 PMCID:PMC4103691

[92] Wilting RH.Epigenetic mechanisms in tumorigenesis, tumor cell heterogeneity and drug resistance..Drug Resist Updat2012;15:21-38

[93] Hoey T.Drug resistance, epigenetics, and tumor cell heterogeneity..Sci Transl Med2010;2:28ps19

[94] Zeller C.Therapeutic modulation of epigenetic drivers of drug resistance in ovarian cancer..Ther Adv Med Oncol2010;2:319-29 PMCID:PMC3126026

[95] Ohata Y,Akiyama Y,Nakao K.Acquired resistance with epigenetic alterations under long-term anti-angiogenic therapy for hepatocellular carcinoma..Mol Cancer Ther2017;16:1155-65

[96] Chen QN,Wang ZX.Long non-coding RNAs in anti-cancer drug resistance..Oncotarget2017;8:1925-36 PMCID:PMC5352108

[97] Malek E,Driscoll JJ.Correlation of long non-coding RNA expression with metastasis, drug resistance and clinical outcome in cancer..Oncotarget2014;5:8027-38 PMCID:PMC4226665

[98] Fan Y,Tan M,Qin Y.Long non-coding RNA UCA1 increases chemoresistance of bladder cancer cells by regulating Wnt signaling..FEBS J2014;281:1750-8

[99] Chen X,Wu S.The Warburg effect: evolving interpretations of an established concept..Free Radic Biol Med2015;79:253-63 PMCID:PMC4356994

[100] Bashashati A,Tone A,Prentice LM.Distinct evolutionary trajectories of primary high-grade serous ovarian cancers revealed through spatial mutational profiling..J Pathol2013;231:21-34 PMCID:PMC3864404

[101] Gerlinger M,Horswell S,Larkin J.Intratumor heterogeneity and branched evolution revealed by multiregion sequencing..N Engl J Med2012;366:883-92 PMCID:PMC4878653

[102] Navin N,Rodgers L,Meth J.Inferring tumor progression from genomic heterogeneity..Genome Res2010;20:68-80 PMCID:PMC2798832

[103] Landau DA,Stojanov P,Stevenson K.Evolution and impact of subclonal mutations in chronic lymphocytic leukemia..Cell2013;152:714-26 PMCID:PMC3575604

[104] Burrell RA.Tumour heterogeneity and the evolution of polyclonal drug resistance..Mol Oncol2014;8:1095-111 PMCID:PMC5528620

[105] Chen W,Lv M,Zhao JH.Exosomes from drug-resistant breast cancer cells transmit chemoresistance by a horizontal transfer of microRNAs..PLoS One2014;9:e95240 PMCID:PMC3989268

[106] Hanahan D.Hallmarks of cancer: the next generation..Cell2011;144:646-74

[107] Hanahan D.Accessories to the crime: functions of cells recruited to the tumor microenvironment..Cancer Cell2012;21:309-22

[108] Casey JR,Orlowski J.Sensors and regulators of intracellular pH..Nat Rev Mol Cell Biol2010;11:50-61

[109] Swietach P,Harris AL.The chemistry, physiology and pathology of pH in cancer..Philos Trans R Soc Lond B Biol Sci2014;369:20130099 PMCID:PMC3917353

[110] Sharma M,Soi S,Shetty D.pH gradient reversal: an emerging hallmark of cancers..Recent Pat Anticancer Drug Discov2015;10:244-58

[111] Taylor S,Assaraf YG,Rauch C.Microenvironment acidity as a major determinant of tumor chemoresistance: proton pump inhibitors (PPIs) as a novel therapeutic approach..Drug Resist Updat2015;23:69-78

[112] Webb BA,Jacobson MP.Dysregulated pH: a perfect storm for cancer progression..Nat Rev Cancer2011;11:671-7

[113] Wojtkowiak JW,Schramm KJ.Drug resistance and cellular adaptation to tumor acidic pH microenvironment..Mol Pharm2011;8:2032-8 PMCID:PMC3230683

[114] Azzarito T,Cesolini A.Lansoprazole induces sensitivity to suboptimal doses of paclitaxel in human melanoma..Cancer Lett2015;356:697-703

[115] Quail DF,Akkari L,Quick ML.The tumor microenvironment underlies acquired resistance to CSF-1R inhibition in gliomas..Science2016;352:aad3018 PMCID:PMC5450629

[116] De Palma M.Macrophage regulation of tumor responses to anticancer therapies..Cancer Cell2013;23:277-86

[117] Tap WD,Anthony SP,Zhang C.Structure-guided blockade of CSF1R kinase in tenosynovial giant-cell tumor..N Engl J Med2015;373:428-37

[118] Pyonteck SM,Schuhmacher AJ,Sevenich L.CSF-1R inhibition alters macrophage polarization and blocks glioma progression..Nat Med2013;19:1264-72 PMCID:PMC3840724

[119] Ries CH,Hoves S,Wartha K.Targeting tumor-associated macrophages with anti-CSF-1R antibody reveals a strategy for cancer therapy..Cancer Cell2014;25:846-59

[120] Reynolds TY,Glazer PM.Genetic instability induced by the tumor microenvironment..Cancer Res1996;56:5754-7

[121] Bindra RS.Genetic instability and the tumor microenvironment: towards the concept of microenvironment-induced mutagenesis..Mutat Res Mol Mech Mutagen2005;569:75-85

[122] Fischer KR,Lee S,Li F.Epithelial-to-mesenchymal transition is not required for lung metastasis but contributes to chemoresistance..Nature2015;527:472-6 PMCID:PMC4662610

[123] Du B.Targeting epithelial-mesenchymal transition (EMT) to overcome drug resistance in cancer..Molecules2016;21:965 PMCID:PMC6273543

[124] Brunen D,Kellner U,Simon I.TGF-β: an emerging player in drug resistance..Cell Cycle2013;12:2960-8 PMCID:PMC3875670

[125] Oshimori N,Fuchs E.TGF-β promotes heterogeneity and drug resistance in squamous cell carcinoma..Cell2015;160:963-76 PMCID:PMC4509607

[126] Li J,Yu J.Chemoresistance to doxorubicin induces epithelial-mesenchymal transition via upregulation of transforming growth factor β signaling in HCT116 colon cancer cells..Mol Med Rep2015;12:192-8 PMCID:PMC4438913

[127] Bhola NE,Dugger TC,Sánchez V.TGF-β inhibition enhances chemotherapy action against triple-negative breast cancer..J Clin Invest2013;123:1348-58 PMCID:PMC3582135

[128] Wu Y,Kim J,Chung S.Expression of Wnt3 activates Wnt/β-catenin pathway and promotes EMT-like phenotype in trastuzumab-resistant HER2-overexpressing breast cancer cells..Mol cancer Res MCR2012;10:1597-606 PMCID:PMC3732195

[129] Della Corte CM,Vicidomini G,Malapelle U.SMO gene amplification and activation of the hedgehog pathway as novel mechanisms of resistance to anti-epidermal growth factor receptor drugs in human lung cancer..Clin Cancer Res2015;21:4686-97

[130] Shibue T.EMT, CSCs, and drug resistance: the mechanistic link and clinical implications..Nat Rev Clin Oncol2017;14:611-29 PMCID:PMC5720366

[131] Deng JJ,Xu XM,Tao WP.Twist mediates an aggressive phenotype in human colorectal cancer cells..Int J Oncol2016;48:1117-24

[132] Haslehurst AM,Dharsee M,Evans K.EMT transcription factors snail and slug directly contribute to cisplatin resistance in ovarian cancer..BMC Cancer2012;12:91 PMCID:PMC3342883

[133] Siebzehnrubl FA,Tugertimur B,Siebzehnrubl D.The ZEB1 pathway links glioblastoma initiation, invasion and chemoresistance..EMBO Mol Med2013;5:1196-212 PMCID:PMC3944461

[134] Lazarova D.ZEB1 mediates drug resistance and EMT in p300-deficient CRC..J Cancer2017;8:1453-9 PMCID:PMC5479251

[135] Zhou Z,Xie B,Yang X.FOXC2 promotes chemoresistance in nasopharyngeal carcinomas via induction of epithelial mesenchymal transition..Cancer Lett2015;363:137-45

[136] Zheng X,Kim J,Kaye J.Epithelial-to-mesenchymal transition is dispensable for metastasis but induces chemoresistance in pancreatic cancer..Nature2015;527:525-30 PMCID:PMC4849281

[137] Saxena M,Pathak H.Transcription factors that mediate epithelial-mesenchymal transition lead to multidrug resistance by upregulating ABC transporters..Cell Death Dis2011;2:e179 PMCID:PMC3199722

[138] Zhu K,Han X,Wang J.Short hairpin RNA targeting Twist1 suppresses cell proliferation and improves chemosensitivity to cisplatin in HeLa human cervical cancer cells..Oncol Rep2012;27:1027-34 PMCID:PMC3583405

[139] Tsou SH,Hsiao HT.A critical dose of doxorubicin is required to alter the gene expression profiles in MCF-7 cells acquiring multidrug resistance..PLoS One2015;10:e0116747 PMCID:PMC4312059

[140] Li W,Tang Y,Zhou F.Overexpression of Snail accelerates adriamycin induction of multidrug resistance in breast cancer cells..Asian Pac J Cancer Prev2011;12:2575-80

[141] Chen WJ,Tang Y,Li HL.Multidrug resistance in breast cancer cells during epithelial-mesenchymal transition is modulated by breast cancer resistant protein..Chin J Cancer2010;29:151-7

[142] Hamada S,Hirota M,Umino J.The homeobox gene MSX2 determines chemosensitivity of pancreatic cancer cells via the regulation of transporter gene ABCG2..J Cell Physiol2012;227:729-38

[143] Lee SH,Do SI,Kang HJ.SOX2 regulates self-renewal and tumorigenicity of stem-like cells of head and neck squamous cell carcinoma..Br J Cancer2014;111:2122-30 PMCID:PMC4260038

[144] Mato E,Moral A,Bell O.ABCG2/BCRP gene expression is related to epithelial-mesenchymal transition inducer genes in a papillary thyroid carcinoma cell line (TPC-1)..J Mol Endocrinol2014;52:289-300

[145] Sun L,He Z,Huang Q.HES1 promotes colorectal cancer cell resistance to 5-Fu by inducing of EMT and ABC transporter proteins..J Cancer2017;8:2802-8 PMCID:PMC5604212

[146] Uchibori K,Sunaga M,Sakurada T.Establishment and characterization of two 5-fluorouracil-resistant hepatocellular carcinoma cell lines..Int J Oncol2012;40:1005-10 PMCID:PMC3584526

[147] Bhuvanalakshmi G,Millward M,Warrier S.Secreted frizzled-related protein 4 inhibits glioma stem-like cells by reversing epithelial to mesenchymal transition, inducing apoptosis and decreasing cancer stem cell properties..PLoS One2015;10:e0127517 PMCID:PMC4452329

[148] Hou Y,Li Z,Yu X.The FOXM1-ABCC5 axis contributes to paclitaxel resistance in nasopharyngeal carcinoma cells..Cell Death Dis2017;8:e2659 PMCID:PMC5386553

[149] Jiang ZS,Wang SM.Epithelial-mesenchymal transition: potential regulator of ABC transporters in tumor progression..J Cancer2017;8:2319-27 PMCID:PMC5560151

[150] Haenisch S,Cascorbi I.MicroRNAs and their relevance to ABC transporters..Br J Clin Pharmacol2014;77:587-96 PMCID:PMC3971975

[151] Lopes-Rodrigues V,Sousa D,Lima RT.The network of P-glycoprotein and microRNAs interactions..Int J Cancer2014;135:253-63

[152] Liu S,Cui R.miR-200c inhibits melanoma progression and drug resistance through down-regulation of Bmi-1..Am J Pathol2012;181:1823-35 PMCID:PMC3483804

[153] Sui H,Pan SF,Wang YW.miR200c attenuates P-gp-mediated MDR and metastasis by targeting JNK2/c-Jun signaling pathway in colorectal cancer..Mol Cancer Ther2014;13:3137-51

[154] Park SM,Lengyel E.The miR-200 family determines the epithelial phenotype of cancer cells by targeting the E-cadherin repressors ZEB1 and ZEB2..Genes Dev2008;22:894-907 PMCID:PMC2279201

[155] Hu J,Jiang F,Yang X.MiR-145 regulates cancer stem-like properties and epithelial-to-mesenchymal transition in lung adenocarcinoma-initiating cells..Tumour Biol2014;35:8953-61

[156] Zhang Z,Shi R.miR-27 promotes human gastric cancer cell metastasis by inducing epithelial-to-mesenchymal transition..Cancer Genet2011;204:486-91

[157] Zhang H,Han Y,Gong T.Down-regulation of miR-27a might reverse multidrug resistance of esophageal squamous cell carcinoma..Dig Dis Sci2010;55:2545-51

[158] An X,Tan T.Regulation of multidrug resistance by microRNAs in anti-cancer therapy..Acta Pharm Sin B2017;7:38-51 PMCID:PMC5237711

[159] Kitamura K,Okano T,Miyanaga A.MiR-134/487b/655 cluster regulates TGF-β-induced epithelial-mesenchymal transition and drug resistance to gefitinib by targeting MAGI2 in lung adenocarcinoma cells..Mol Cancer Ther2014;13:444-53

[160] Kokubo Y,Noro R,Kataoka K.Reduction of PTEN protein and loss of epidermal growth factor receptor gene mutation in lung cancer with natural resistance to gefitinib (IRESSA)..Br J Cancer2005;92:1711-9 PMCID:PMC2362053

[161] Qian Y,Liu Y,Colvin RA.Extracellular ATP is internalized by macropinocytosis and induces intracellular ATP increase and drug resistance in cancer cells..Cancer Lett2014;351:242-51

[162] Pfeiffer T,Bonhoeffer S.Cooperation and competition in the evolution of ATP-producing pathways..Science2001;292:504-7

[163] Pecqueur C,Oizel K,Vallette FM.Targeting metabolism to induce cell death in cancer cells and cancer stem cells..Int J Cell Biol2013;2013:805975 PMCID:PMC3583110

[164] Liu Y,Zhang W,Qian Y.A small-molecule inhibitor of glucose transporter 1 downregulates glycolysis, induces cell-cycle arrest, and inhibits cancer cell growth in vitro and in vivo..Mol Cancer Ther2012;11:1672-82

[165] Warburg O.On the origin of cancer cells..Science1956;123:309-14

[166] Koppenol WH,Dang CV.Otto Warburg’s contributions to current concepts of cancer metabolism..Nat Rev Cancer2011;11:325-37

[167] Vander Heiden MG,Thompson CB.Understanding the Warburg effect: the metabolic requirements of cell proliferation..Science2009;324:1029-33 PMCID:PMC2849637

[168] Zhou Y,Chen J,Xia L.Intracellular ATP levels are a pivotal determinant of chemoresistance in colon cancer cells..Cancer Res2012;72:304-14 PMCID:PMC3601736

[169] Schneider V,Bendas G,Kalayda GV.Contribution of intracellular ATP to cisplatin resistance of tumor cells..J Biol Inorg Chem2013;18:165-74

[170] Ko YH,Wang Y,Rini DA.Advanced cancers: eradication in all cases using 3-bromopyruvate therapy to deplete ATP..Biochem Biophys Res Commun2004;324:269-75

[171] Zhou M,Ding Y,Liu Z.Warburg effect in chemosensitivity: Targeting lactate dehydrogenase-A re-sensitizes Taxol-resistant cancer cells to Taxol..Mol Cancer2010;9:33 PMCID:PMC2829492

[172] Le A,Gouw AM,Maitra A.Inhibition of lactate dehydrogenase A induces oxidative stress and inhibits tumor progression..Proc Natl Acad Sci2010;107:2037-42 PMCID:PMC2836706

[173] Qian Y,Chen X.Inhibitors of glucose transport and glycolysis as novel anticancer therapeutics..World J Transl Med2014;3:37

[174] Ganapathy-Kanniappan S.Tumor glycolysis as a target for cancer therapy: progress and prospects..Mol Cancer2013;12:152 PMCID:PMC4223729

[175] Pellegatti P,Bianchi G,Pistoia V.Increased level of extracellular ATP at tumor sites: in vivo imaging with plasma membrane luciferase..PLoS One2008;3:e2599 PMCID:PMC2440522

[176] Falzoni S,Di Virgilio F.Detecting adenosine triphosphate in the pericellular space..Interface Focus2013;3:20120101 PMCID:PMC3638417

[177] Michaud M,Sukkurwala AQ,Ma Y.Autophagy-dependent anticancer immune responses induced by chemotherapeutic agents in mice..Science2011;334:1573-7

[178] Wilhelm K,Müller T,Grimm M.Graft-versus-host disease is enhanced by extracellular ATP activating P2X7R..Nat Med2010;16:1434-8

[179] Wang X,Qian Y,Shriwas P.Extracellular ATP, as an energy and phosphorylating molecule, induces different types of drug resistances in cancer cells through ATP internalization and intracellular ATP level increase..Oncotarget2017;8:87860-77 PMCID:PMC5675678

[180] Qian Y,Li Y,Chen X.Extracellular ATP a new player in cancer metabolism: NSCLC cells internalize ATP in vitro and in vivo using multiple endocytic mechanisms..Mol Cancer Res2016;14:1087-96

[181] Di Virgilio F,Falzoni S,Adinolfi E.Extracellular ATP and P2 purinergic signalling in the tumour microenvironment..Nat Rev Cancer2018;18:601-18

[182] Di Virgilio F,Adinolfi E.P2X(7): a growth-promoting receptor-implications for cancer..Purinergic Signal2009;5:251-6 PMCID:PMC2686832

[183] Burnstock G.Purinergic signalling and cancer..Purinergic Signal2013;9:491-540 PMCID:PMC3889385

[184] Vinette V,Arguin G.Multidrug resistance-associated protein 2 expression is upregulated by adenosine 5’-triphosphate in colorectal cancer cells and enhances their survival to chemotherapeutic drugs..PLoS One2015;10:e0136080 PMCID:PMC4546675

[185] Deli T,Ádám A,Rásó E.Functional genomics of calcium channels in human melanoma cells..Int J Cancer2007;121:55-65

[186] Limami Y,Leger DY,Delage C.The P2Y2/Src/p38/COX-2 pathway is involved in the resistance to ursolic acid-induced apoptosis in colorectal and prostate cancer cells..Biochimie2012;94:1754-63

[187] Morrone FB,Gamermann P,Wofchuk S.In vivo glioblastoma growth is reduced by apyrase activity in a rat glioma model..BMC Cancer2006;6:226 PMCID:PMC1592110

[188] Elliott MR,Trampont PC,Kadl A.Nucleotides released by apoptotic cells act as a find-me signal to promote phagocytic clearance..Nature2009;461:282-6 PMCID:PMC2851546

[189] Galluzzi L,Kepp O,Kroemer G.Immunogenic cell death in cancer and infectious disease..Nat Rev Immunol2017;17:97-111

[190] Ko A,Martins I,Chargari C.Autophagy inhibition radiosensitizes in vitro, yet reduces radioresponses in vivo due to deficient immunogenic signalling..Cell Death Differ2014;21:92-9 PMCID:PMC3857616

[191] Galluzzi L,Kroemer G.Enlightening the impact of immunogenic cell death in photodynamic cancer therapy..EMBO J2012;31:1055-7 PMCID:PMC3298006

[192] Ghiringhelli F,Tesniere A,Ma Y.Activation of the NLRP3 inflammasome in dendritic cells induces IL-1β-dependent adaptive immunity against tumors..Nat Med2009;15:1170-8

[193] Filippini A,Sitkovsky MV.Extracellular ATP in T-lymphocyte activation: possible role in effector functions..Proc Natl Acad Sci U S A1990;87:8267-71 PMCID:PMC54936

[194] Piccini A,Tassi S,Fossati G.ATP is released by monocytes stimulated with pathogen-sensing receptor ligands and induces IL-1 and IL-18 secretion in an autocrine way..Proc Natl Acad Sci2008;105:8067-72 PMCID:PMC2430360

[195] Antonioli L,Vizi ES.CD39 and CD73 in immunity and inflammation..Trends Mol Med2013;19:355-67 PMCID:PMC3674206

[196] Regateiro FS,Waldmann H.CD73 and adenosine generation in the creation of regulatory microenvironments..Clin Exp Immunol2013;171:1-7 PMCID:PMC3530089

[197] Stagg J.Extracellular adenosine triphosphate and adenosine in cancer..Oncogene2010;29:5346-58

[198] Ohta A.A metabolic immune checkpoint: adenosine in tumor microenvironment..Front Immunol2016;7:109 PMCID:PMC4809887

[199] Yang H,Chen G,Yamazaki T.Contribution of RIP3 and MLKL to immunogenic cell death signaling in cancer chemotherapy..Oncoimmunology2016;5:e1149673 PMCID:PMC4938314

[200] Kaiser J.When less is more..Science2017;355:1144-6

[201] Moriceau G,Hong A,Kong X.Tunable-combinatorial mechanisms of acquired resistance limit the efficacy of BRAF/MEK cotargeting but result in melanoma drug addiction..Cancer Cell2015;27:240-56 PMCID:PMC4326539

[202] Amin AD,Liang WS,Groysman MJ.Evidence suggesting that discontinuous dosing of ALK kinase inhibitors may prolong control of ALK+ tumors..Cancer Res2015;75:2916 PMCID:PMC4506255

[203] Hay N.Reprogramming glucose metabolism in cancer: can it be exploited for cancer therapy?.Nat Publ Gr2016;16:635-49 PMCID:PMC5516800

[204] Zhu A,Shim H.Metabolic positron emission tomography imaging in cancer detection and therapy response..Semin Oncol2011;38:55-69 PMCID:PMC3075495

[205] Cairns RA,Mak TW.Regulation of cancer cell metabolism..Nat Rev Cancer2011;11:85-95